Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-08-21
2000-01-11
Allen, Marianne P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3817, A61K 3822, C07K 1458
Patent
active
060136308
ABSTRACT:
The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.
REFERENCES:
patent: 5665704 (1997-09-01), Lowe et al.
Barnett, 1988, "Cerebral ischemia and infarction" Cecil Textbook of Medicine (W.B. Saunders Co., Philadelphia) pp. 2162-2173.
Boers et al., 1985, "Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease", N. Eng. J. Med. 313:709-715.
Brass et al., 1991, "A study of twins and stroke", Stroke 23:221-223.
Calabresisi et al., 1970, "Effects of treatment on morbidity in hypertension", JAMA 213:1143-1152.
Chang et al., 1996, "Natriuretic peptide receptors on human trabecular meshwork cells", Curr. Eye Res. 15:137-143.
de leon et al., 1994, "Rat renal preglomerular vessels, glomeruli and papillae do not express detectable quantities of B-type natriuretic peptide receptor", J. Hypertens. 12:539-548.
DeFaire et al., 1975, "Concordance for mortality with special reference to ischemic heart disease and cerebrovascular disease", Prev. Med. 4:509-517.
Estrada et al., 1994, "High plasma levels of endothelial-1 and atrial natriuretic peptide in patients with acute ischemic stroke", Am. J. Hypertens. 7:1085-1089.
Garcia et al., 1989, "Glomerular atrial natriuretic factor receptors in spontaneously hypertensive rats", Hypertension 13:567-574.
GenBank Accession No. M30262.
GenBank Accession No. K02062, K02063.
He et al., 1995, "High-yield affinity alkylation of the atrial natriuretic factor receptor binding site", Bioconjugate Chem. 6:541-548.
Hutter, 1995, "Ischemic heart disease: Angina pectoris" Scientific American: Medicine, vol. 1 (Scientific American, Inc., New York) Chapter 1 pp. 1-19.
Iwashina et al., 1994, "His.sup.145 --Trp.sup.146 residues and the disulfide-linked loops in atrial natriuretic peptide receptor are critical for the ligand-binding activity", J. Biochem. 115:563-567.
Jeffs et al., 1997, "Sensitivity to cerebral ischemic insult in a rat model of stroke is determined by a single genetic locus", Nat. Gen. 16:364-367.
Kannel et al., 1970, "Epidemiologic assessment of the role of blood pressure in stroke", JAMA 214:301-310.
Levy et al., 1990, "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", Science 248:1124-1126.
Miao et al., 1995, "Mutational inactivation of the catalytic domain of guanylate cyclase-A receptor", Hypertension 25:694-698.
Nascimenato-Gomes et al., 1995, "Atrial natriuretic peptide modulates the effect of angiotensin II on the concentration of free calcium in the cytosol of Mandin-Darby canine kidney cells", Brazil. J. of Med. & Biol. Res. 28:609-613.
Needleman et al., 1989, "The biochemical pharmacology of atrial peptides", Ann. Rev. Pharmacol. Toxicol. 29:23-54.
Palsdottir et al., 1988, "Mutation in cystatin c gene causes hereditary brain haemorrhage", Lancet 2:603-604.
Rubattu et al., "Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease", Nat. Gen. 13:429-434.
Schulz et al., 1989, "The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family", Cell 58:1155-1162.
Vesely et al., 1996, "Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans", Life Sciences 59:243-254.
Vesely et al., 1996, "Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans", Metabolism: Clinical & Experimental 45:315-319.
Vesely et al., 1992, "Specific binding site for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes", Renal Phys. & Biochem. 15:23-32.
Vesely et al., 1995, "Atrial natriuretic peptides and cyclic guanosine monophosphate metabolism", Amer. J. Med. Sci. 310:143-149.
Yatsu et al., 1997, "Cerebrovascular disorders" Scientific American: Medicine, vol. 3 (Scientific American, Inc., New York (Chapter 11 pp. 1-12.
Veterans Administration Cooperative Study Group on Antihypertensive Agents, 1970. "Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg." JAMA. 213:1143-1152.
Okayama, et al., 1989. "Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification." J Lab Clin Med. 114: 105-113.
Reuters Health Information. 1998. "Gene mutation may double stroke risk." MedScape News Headlines, Sep. 23, 1998. URL:http://www.medscape.com/reuters/thu/t0923-4f.html.
Rubattu, et al., 1998. "Identification of a genetic determinant of stroke, the gene encoding the atrial natriuretic peptide (ANP)." Conference Abstract: Impact of Rat Genome Mapping on Biomedical Research, Oct. 4-6, 1998. Medical School Hannover, Lower Saxony, Germany. Pg V/3.
Shilo, et al., 1981. "DNA sequences homologous to vertebrate oncogenes are conserved in Drosophilia melanogaster." Proc Natl Acad Sci USA. 78: 6789-6792.
Sommer, et al., 1992. "PCR amplification of specific alleles (PASA) is a general method for rapidly detecting known single-base changes." BioTechniques. 12: 82-87.
Vesely, et al., 1996. "Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans." Metabolism: Clin & Exp. 45: 315-319.
Allen Marianne P.
CuraGen Corporation
Elrifi Ivor R.
Johnson David E.
LandOfFree
Atrial natriuretic factor mutants and ischemic stroke does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Atrial natriuretic factor mutants and ischemic stroke, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Atrial natriuretic factor mutants and ischemic stroke will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1462447